Abstract
The rationale for combination of cisplatin and carboplatin is based primarily on 1) a steep dose-response in antitumor effects of platinums, and 2) the widely different dose-limiting toxicities for cisplatin and carboplatin. With the introduction of several new analogues, the rationale of lack of complete cross-resistance becomes increasingly attractive. In fact, both preclinical and clinical data have been assembled in support of the hypothesis that combinations of platinum compounds may lead to improved therapeutic effects. We review here the issues concerned with specific platinum combinations and illustrate possible strategies to test such combinations, and preliminary clinical experience.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
D.T. Trump, J.L. Grem, K.D. Tutsch, J.K.V. Willson, K.J. Simon, D. Alberti, B. Storer, and D.C. Tormey. Platinum analogue combination chemotherapy: cisplatin and carboplatin — a Phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J. Clin. Oncol. 5:1281, (1987).
F.M. Muggia and I. Gill. Optimizing dose-intensity: combining carboplatin with cisplatin, in: “Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy”, S.B. Howell, ed., Plenum, New York (1991).
C. Sessa, A. Goldhirsch, G. Martinelli, M. Alerci, L. Imburgia, and F. Cavalli. Phase I study of the combination of monthly carboplatin and weekly cisplatin, Ann. Oncol 2:123(1991).
K. Kobayashi, A. Yoshimura, M. Hino, A. Gemma, K. Yoshimori, M. Shibuya, T. Takemoto, K. Hayashihara, M. Matsuzaka, S. Wasai, and H. Niitani. Combination of cisplatin and carboplatin in vitro and in clinical practice, in: “Cancer Chemotherapy — Challenges for the Future”, Volume 8, edited by K. Kimura, H. Saito, S.K. Carter, and R.C. Bast, Jr., Excerpta Medica, Tokyo, 1992.
F.A. Blommaert, C. Michael, P.A.B. Terheggen, F.M. Muggia, V. Kortes, J.H. Schornagel, A.A.M. Hart, and L. den Engelse. Drug-induced DNA modification in buccal cells of cancer patients during carboplatin and cisplatin combination chemotherapy as determined by an immunocytochemical method: interindividual variations and correlation with disease response, Cancer Res 53:5669, (1994).
B. Uziely, S.C. Formenti, K. Watkins, A. Mazumder, and F.M. Muggia. Calvert’s formula and high-dose carboplatin, J. Clin. Oncol. 12:1740, (1994)
M.J. Piccart, J.M. Nogaret, L. Marcelis, H. Longree, F. Ries, J.P. Kainds, P. Gobert, A.M. Domage, J.P. Sculier, G. Gompel and the Belgian Study Group for Ovarian Carcinoma. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in treatment of ovarian cancer, J. Clin. Oncol. 2:1281(1987).
B. Lund, M. Hansen, O.P. Hansen, and H.H. Hansen. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease, J. Clin. Oncol. 7:1469 (1989).
B. Lund, M. Hansen, O.P. Hansen, and H.H. Hansen. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease, J. Clin. Oncol. 8:1226 (1990).
B. Lund, O.P. Hansen, H.H. Hansen, and M. Hansen. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Sem Oncol. 19(1):26 (1992).
J.R. Hardy, E. Wiltshaw, P.R. Blake, P. Harper, M. Slevin, T.J. Perrin, and S. Tan. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann. Oncol. 2:131 (1991).
E. Reed (Personal communication).
G. Bolis (to be published, 1995).
F. Muggia, L. Muderspach, L. Roman, S. Jeffers, S. Groshen, P. Conti, S.E. Martin, and C.P. Morrow. Phase I/II study of intraperitoneal floxuridine (FUDR) with either cisplatin or carboplatin or both, Proc. Amer. Soc. Clin. Oncol. 14:(1995).
J.P. Caussavel, F. Levi, S. Brienza, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate, J. Natl. Cancer Inst. 82:1046, (1990)
G. Mathe, E. Chenu, C. Bourut, et al. Experimental study of three platinum complexes: CDDP, CBDCA and l-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes, Proc. Amer. Assoc. Cancer Res. 30:1872(1989).
J.F. Llory, P. Soulie, E. Cvitkovic, and J.L. Misset. Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin, J. Natl. Cancer Inst. 86:1098(1994).
P. Soulie, E. Cvitkovic, C. Garrino, M. Frereres, K. Azzouzi, J.F. Llory, M. Musset, J. Gastiaburu, and J.L. Misset. Combined oxaliplatin (1-OHP) cisplatin: an effective approach to optimize platinum treatment of malignancies, Proc. Amer. Assoc. Cancer Res. 35:438 (1994).
E. Cvitkovic, M. Frereres, P. Soulie, J.F. Llory, O. Rixe, C. Garrino, M. Marty, and J.L. Misset. High activity in pretreated germ cell tumors of combined oxaliplatin (l-OHP) cisplatin based salvage regimen, Proc. Amer. Assoc. Cancer Res. 35:233 (1994).
J.L. Misset, P. Soulie, M. Frereres, J.F. Llory, E. Raymond, M. Musset, P. Chollet, C. Jasmin, C. Garrino, and E. Cvitkovic. High efficacy of combined oxaliplatin (l-OHP) cisplatin as salvage treatment in pretreated ovarian cancer, Proc. Amer. Assoc. Cancer Res. 35:234 (1994).
C. Garrino, E. Cvitkovic, P. Soulie, M. Frereres, E. Brain, S. Brienza, M. Itzhaki, C. Jasmin, and J.L. Misset. Toxicity patterns of the oxaliplatin/cisplatin association alone or with ifosfamide/epiadriamycin to platinum pretreated patients, Proc. Amer. Assoc. Cancer Res. 35:244 (1994).
J.A. Gietema, E.G. DeVries, D.T. Sleijfer, P.H. Willemse, H.J. Guchelaar, D.R. Uges, P. Aulenbacher, R. Voegeli, N.H. Mulder. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Brit. J. Cancer 67:396 (1993).
M.J. McKeage, L.R. Kelland, F.E. Boxal, M.R. Valenti, M. Jones, P.M. Goddard, J. Gwynne, and K.R. Harrap. Schedule dependency of orally administered bis-acetato-amminedichloro-cyclohexylamine-platinum (IV) (JM216) in vivo, Cancer Res. 54:4118 (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Muggia, F.M. (1996). Combination of Different Platinum Compounds: Issues, Strategies, and Experience. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_15
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0218-4_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0220-7
Online ISBN: 978-1-4899-0218-4
eBook Packages: Springer Book Archive